{
    "clinical_study": {
        "@rank": "19846", 
        "arm_group": {
            "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
            "arm_group_type": "Experimental", 
            "description": "Patients treated with Allopurinol, Keppra, Busulfan, Cyclophosphamide, Filgrastim, antithymocyte globulin, cyclosporine A, Mycophenolate mofetil and allogeneic hematopoietic stem cell transplant infusion."
        }, 
        "brief_summary": {
            "textblock": "This is a treatment guideline to allow routine clinical data to be collected and maintained\n      in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as\n      part of the historical database maintained by the department."
        }, 
        "brief_title": "Busulfan and Cyclophosphamide Followed By ALLO BMT", 
        "completion_date": {
            "#text": "September 2022", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Lymphoblastic Leukemia", 
            "Acute Myeloid Leukemia", 
            "Myelodysplastic Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia", 
                "Hematologic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a single arm trial to evaluate the efficacy of busulfan and cyclophosphamide\n      followed by an allogeneic hematopoietic stem cell transplant (HSCT) in the treatment of\n      hematological malignancies.  The intent of this study is to provide a protocol that will use\n      unmanipulated allogeneic hematopoietic stem cells from related and unrelated donors after a\n      common preparative regimen. Results will be compared to historical controls."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) or\n             myelodysplastic syndrome (MDS) and current in complete remission meeting one of the\n             following:\n\n               -  <45 years of age who are at least 6 months after initial hematopoietic stem cell\n                  transplant (HSCT)\n\n               -  <45 years of age and have received sufficient radiation treatment to be\n                  ineligible for total body irradiation (TBI) containing preparative therapy\n\n          -  Karnofsky performance status >70% or if <16 years of age, a Lansky play score >50\n\n          -  Adequate major organ function including:\n\n               -  cardiac: left ventricular ejection fraction >45% by echocardiogram (ECHO/MUGA)\n\n               -  renal: creatinine clearance >40 mL/min/1.73m^2\n\n               -  hepatic: no clinical evidence of hepatic failure (e.g., coagulopathy, ascites)\n\n          -  An acceptable source of stem cells according to current University of Minnesota Bone\n             Marrow Transplant program guidelines. Acceptable stem cell sources include:\n\n               -  HLA-matched related or unrelated donor bone marrow (6/6 or 5/6 antigen match)\n\n               -  HLA-matched related or unrelated donor peripheral blood stem cells\n\n               -  related or single or double unrelated donor umbilical cord blood (6/6, 5/6 or\n                  4/6 match)\n\n          -  Women of childbearing age must have a negative pregnancy test and all sexually active\n             participants must agree to use effective contraception during study treatment\n\n          -  Written consent (adult or parent/guardian)\n\n        Exclusion Criteria:\n\n          -  eligible for TBI containing preparative regimen\n\n          -  active uncontrolled infection within one week of study enrollment\n\n          -  pregnant or lactating female"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "44 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685411", 
            "org_study_id": "2011OC139", 
            "secondary_id": "MT2011-20C"
        }, 
        "intervention": [
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Day -8 (prior to transplant): Per institutional guidelines", 
                "intervention_name": "Allopurinol", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Lopurin", 
                    "Zyloprim"
                ]
            }, 
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Day -8 (prior to transplant): Per institutional guidelines", 
                "intervention_name": "Keppra", 
                "intervention_type": "Drug", 
                "other_name": "Levetiracetam"
            }, 
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.", 
                "intervention_name": "Busulfan", 
                "intervention_type": "Drug", 
                "other_name": "Myleran"
            }, 
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Cytoxan"
            }, 
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Day -3  (prior to transplant) and will be administered by mouth/intravenously (PO/IV) maintaining a trough level between 200 and 400 ng/mL. Adult initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. Children < 40 kg will be 2.5 mg/kg IV over 2 hours every 8 hours.", 
                "intervention_name": "Cyclosporine A", 
                "intervention_type": "Drug", 
                "other_name": "CSA"
            }, 
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (> or = 40 kg) or 15 mg/kg 3 times per day (< 40 kg) for up to 30 days unless no engraftment.", 
                "intervention_name": "Mycophenolate mofetil", 
                "intervention_type": "Drug", 
                "other_name": "MMF"
            }, 
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.", 
                "intervention_name": "Allogeneic hematopoietic stem cell transplant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is >2500 x 10^9/L or per institutional guidelines.", 
                "intervention_name": "Filgrastim", 
                "intervention_type": "Biological", 
                "other_name": [
                    "G-CSF", 
                    "Granulocyte-colony stimulating factor"
                ]
            }, 
            {
                "arm_group_label": "Allogeneic Hematopoietic Stem Cell Transplant", 
                "description": "Administered per institutional guidelines for recipients of umbilical cord blood transplant.", 
                "intervention_name": "antithymocyte globulin", 
                "intervention_type": "Biological", 
                "other_name": "ATG"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Allopurinol", 
                "Cyclosporins", 
                "Cyclosporine", 
                "Mycophenolic Acid", 
                "Cyclophosphamide", 
                "Antilymphocyte Serum", 
                "Busulfan", 
                "Mycophenolate mofetil", 
                "Lenograstim", 
                "Etiracetam"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "macmi002@umn.edu", 
                "last_name": "Margaret L. MacMillan, M.D.", 
                "phone": "612-626-2778"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "Masonic Cancer Center, University of Minnesota"
            }, 
            "investigator": {
                "last_name": "Margaret L. MacMillan, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Busulfan and Cyclophosphamide Followed By Allogeneic Hematopoietic Cell Transplantation In Patients With Hematological Malignancies", 
        "overall_contact": {
            "email": "macmi002@umn.edu", 
            "last_name": "Margaret L. MacMillan, M.D.", 
            "phone": "612-626-2778"
        }, 
        "overall_official": {
            "affiliation": "Masonic Cancer Center, University of Minnesota", 
            "last_name": "Margaret L. MacMillan, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2022", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.", 
                "measure": "Disease Free Survival", 
                "safety_issue": "No", 
                "time_frame": "2 Years"
            }, 
            {
                "description": "The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.", 
                "measure": "Disease Free Survival", 
                "safety_issue": "No", 
                "time_frame": "5 Years"
            }, 
            {
                "description": "The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.", 
                "measure": "Disease Free Survival", 
                "safety_issue": "No", 
                "time_frame": "10 Years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685411"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm^3 (0.5 x 10^9/L) or greater.", 
                "measure": "Days to Neutrophil Engraftment", 
                "safety_issue": "No", 
                "time_frame": "By Day 42"
            }, 
            {
                "description": "Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.", 
                "measure": "Incidence of Acute Graft-Versus-Host Disease", 
                "safety_issue": "Yes", 
                "time_frame": "Day 100"
            }, 
            {
                "description": "Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.", 
                "measure": "Incidence of Chronic Graft-Versus-Host Disease", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months and 1 Year"
            }, 
            {
                "description": "In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation.", 
                "measure": "Incidence of Treatment-Related Toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months and 1 Year"
            }, 
            {
                "description": "The return of disease after its apparent recovery/cessation.", 
                "measure": "Incidence of Relapse", 
                "safety_issue": "No", 
                "time_frame": "1 Year and 2 Years"
            }, 
            {
                "description": "Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.", 
                "measure": "Incidence of Engraftment Failure", 
                "safety_issue": "No", 
                "time_frame": "Day 42"
            }, 
            {
                "description": "Overall survival will be defined as time from date of enrollment to date of death or censored at the date of last documented contact for patients still alive.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "2 Years, 5 Years and 10 Years"
            }
        ], 
        "source": "Masonic Cancer Center, University of Minnesota", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Masonic Cancer Center, University of Minnesota", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}